Global Contraceptive Drugs Market Size study & Forecast, by Product ( Oral, Injectable , Patches), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channels, Public Channels & NGOs and Others) and Regional Analysis, 2022-2029

Global Contraceptive Drugs Market Size study & Forecast, by Product ( Oral, Injectable , Patches), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channels, Public Channels & NGOs and Others) and Regional Analysis, 2022-2029

Global Contraceptive Drugs Market is valued approximately USD 16.59 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 7.4% over the forecast period 2022-2029. Contraceptive Drugs are consumed by female for birth control. The Contraceptive Drugs market is expanding because of factors such as increasing prevalence of unwanted pregnancies and increasing prevalence of sexually transmitted diseases (STDs). However, rising prevalence of infertility and adverse effects associated with the use of contraceptive drugs and devices may halt market growth.

Throughout the forecast period, the market growth is anticipated to be driven by the rising incidence of Sexually Transmitted Diseases (STDs) and the rising number of women with unmet need for contraceptive medications & devices. Almost 1.1 billion women worldwide in 2019 who are reproductive age (15 to 49 years) need family planning, according to the World Health Organization. Over 842 million of them use contraceptive techniques for family planning, and 270 million of them have unmet contraception needs. Furthermore, The Department of Economic and Social Affairs, Population Division of the United Nations reports that in 2019 that there are 1.9 billion women in the world who are reproductive age (15–49). Around 80 million people utilize conventional methods, while about 842 million women use contemporary contraception, including oral medications and injectables. In addition, growing awareness regarding contraceptive drugs leads to product demand creating a lucrative growth to the market. Along with these, wide availability of reimbursement policies in developed countries is expected to fuel the market adoption rate in the forecasted period.

The key regions considered for the Global Contraceptive Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and the region's increasing disease prevalence. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for biosimilar development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
Piramal Enterprises Ltd.
Organon group of companies
Johnson & Johnson Services, Inc.
AbbVie Inc.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Viatris Inc.
Amneal Pharmaceuticals, Inc.
Bayer AG
Agile Therapeutics.

Recent Developments in the Market:
 In February 2020, The U.S. FDA has authorized Agile Therapeutics to commercialize Twirla (levonorgestrel and ethinyl estradiol), a transdermal patch for women.
 In January 2020, Bayer AG and Daré Bioscience, Inc. have signed a licence agreement to distribute Ovaprene after the U.S. Food and Drug Administration gives the experimental contraception medicine market clearance.

Global Contraceptive Drugs Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Oral
Injectable
Patches
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Clinics
Online Channels
Public Channels & NGOs
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned
Piramal Enterprises Ltd.
Organon group of companies
Johnson & Johnson Services, Inc.
AbbVie Inc.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Viatris Inc.
Amneal Pharmaceuticals, Inc.
Bayer AG
Agile Therapeutics.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.